Related Experiment Video
Updated: May 4, 2026
07:33
Intralymphatic Immunotherapy and Vaccination in Mice
Published on: February 2, 2014
22.5K
New Frontiers in Subcutaneous Immunoglobulin Treatment
Stephen Jolles1, Mark R Stein2, Hilary J Longhurst3
1University Hospital of Wales, Heath Park, Cardiff, CF14 4XW UK.
Biologics in Therapy
|January 7, 2014
Summary
Subcutaneous immunoglobulin (SCIG) offers a safe and convenient alternative to intravenous immunoglobulin (IVIG) for primary immunodeficiency and neuropathies. SCIG effectively initiates treatment and maintains high IgG levels, improving patient outcomes and enabling home therapy.
Area of Science:
- Immunology
- Neurology
- Pharmacology
Background:
- Intravenous immunoglobulin (IVIG) is often preferred for initiating treatment in primary immunodeficiency (PI) and for immunomodulatory therapies requiring high doses.
- Subcutaneous immunoglobulin (SCIG) offers stable serum IgG levels, fewer systemic adverse events, and home therapy convenience compared to IVIG.
Approach:
- Review of recent clinical experience using SCIG as an alternative to IVIG in specific settings.
- Evaluation of SCIG for initiating therapy in newly diagnosed PI patients.
- Assessment of SCIG for maintenance therapy in multifocal motor neuropathy (MMN) and inflammatory myopathies.
Key Points:
- SCIG successfully initiated therapy in 17 of 18 previously untreated PI patients, achieving target IgG levels (≥5 g/L) with good tolerability.
- SCIG demonstrated efficacy and tolerability in MMN patients, maintaining IgG levels (14-22 g/L) and muscle strength with self-administration.
- SCIG therapy improved creatine kinase levels and muscle strength in patients with polymyositis or dermatomyositis.
Conclusions:
- SCIG can be effectively used for initiating immunoglobulin therapy in PI patients, achieving therapeutic IgG levels rapidly.
- SCIG provides a viable and well-tolerated option for maintenance therapy in conditions like MMN, challenging traditional IVIG preferences.
- Recent data suggest SCIG broadens therapeutic options in immunoglobulin replacement and immunomodulatory therapy, supporting its use beyond traditional IVIG indications.
